Jennifer Trowbridge

Functional equivalence of γ- and x-ray irradiation for long-term peripheral blood chimerism and acute myeloid leukemia transplant outcomes in mice Total body irradiation is routinely used for myeloablation before a mouse hematopoietic cell transplant. Widespread transition from 137Cs γ irradiator…

Institutions are phasing out gamma-irradiators, but can X-ray irradiators replace them for mouse transplant models?

We report that with proper dose calibration, X-ray conditioning produces equivalent hematopoietic chimerism and AML transplant outcomes. Encouraging news!

🔗 doi.org/10.1016/j.ex...

This week on #SimplyBlood 🩸 we're sitting down with the 2026 ISEH Vice President Jennifer Trowbridge @trowbridgelab.bsky.social, to hear about upcoming work in her role, the benefits of the ISEH community, advice for trainees and much more➡️ iseh.org/Publications... @macnamaralab.bsky.social

I got the chance to talk to Dr. Jennifer Trowbridge @trowbridgelab.bsky.social about ISEH and how the society supports the hematology community... and what we should be expecting in the year ahead! Have a listen 😊! @isehsociety.bsky.social

Excited to share our latest work on blood aging! To find out why the blood system changes as people age, we started at the source: hematopoietic stem cells (HSCs) #hemesky 🩸🧬 doi.org/10.1101/2025... 🧵 1/5

Celebrate 30 years of #HEMSRC with FASEB! Your research could be presented at the same meeting as hematology experts like @trowbridgelab.bsky.social and @juliamaxson.bsky.social. Submit your abstract by June 1 and save your space: buff.ly/2W1wk85

For 30 years, #HEMSRC has brought together researchers to share their important research. Join organizers @juliamaxson.bsky.social
and Sergei Doulatov alongside keynotes @trowbridgelab.bsky.social and George Vassiliou to network, learn, and find new therapies. Save your space: buff.ly/2QuHlti

Excited to share the @goodell-lab.bsky.social News&Views on 3 exciting studies by Vassiliou Lab, Chan Lab, and @trowbridgelab.bsky.social in @nature.com and @natcomms.nature.com, showing that #DNMT3A mutant (major driver of Clonal Hematopoiesis) blood cells depend on mitochondrial respiration.

Grateful for funding support for this work from NIH, EvansMDS & @llsusa.bsky.social

Congrats to Kira Young who spearheaded this work & all contributing authors. This was a fun (and long!) collaboration with @marcmansour.bsky.social, @challenlab.bsky.social, @ericpietras.bsky.social, Kelsey Fisher-Wellman, @keisukeito-lab.bsky.social & Steven Chan

To me, one of the coolest things about these papers is that three different labs in three different countries (US, Canada, UK) INDEPENDENTLY observed the same foundational phenotype of increased mitochondrial OXPHOS in Dnmt3a-mutant hematopoietic stem & progenitor cells 🇨🇦🇬🇧🇺🇸

Together, we report that mitochondrial activity is a targetable mechanism by which clonal hematopoiesis-mutant HSCs gain a selective advantage over wild-type HSCs.

We find that MitoQ also targets elevated mitochondrial respiration and the selective advantage of human DNMT3A-mutant HSCs, supporting species conservation.

Exploiting elevated mitochondrial membrane potential, we used long-chain alkyl-TPP molecules (ex. MitoQ) that selectively accumulate in the mitochondria. These caused reduced mitochondrial respiration, apoptosis, and ablated the competitive advantage of Dnmt3a-mutant HSCs.

Dnmt3a-mutant HSCs have DNA hypomethylation and increased expression of oxidative phosphorylation gene signatures, increased functional OXPHOS capacity, high
mitochondrial membrane potential & greater dependence on mitochondrial respiration versus wild-type HSCs.

Using a mouse model of Dnmt3a-mutant CH that our lab previously developed, we found that mutant HSCs sustain elevated mitochondrial respiration which is associated with their resistance to aging-induced changes in the bone marrow microenvironment.

Drivers of clonal hematopoiesis include aging and inflammation. How hematopoietic stem cells (HSCs) with somatic mutations gain a selective advantage in these contexts is an unresolved question that we set out to tackle.

Age-related blood condition counteracted with a common diabetes drug Metformin could reduce people’s risk of certain age-associated blood cancers, but more work is needed to identify who is likely to benefit.

New paper from my lab! Elevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis: rdcu.be/eh1Nb Complementary to new work from Steven Chan & @georgevassiliou.bsky.social as described by @goodell-lab.bsky.social: www.nature.com/articles/d41...

I am honored to have been selected by my colleagues to serve a 4-year term as vice president & president of the International Society of Experimental Hematology. Now, as ever, uniting, empowering and inspiring our collective scientific community to press on is essential.

It is an honor to be considered alongside the fantastic @kentlab.bsky.social for the role of Vice President of ISEH. To all @ISEHSociety members: please make an important contribution to the society by voting. It's easy! Good luck to all of the nominees; we are in great hands!!

Happy holidays from the Trowbridge lab! The festive games got a wee bit competitive this year 😅 Thanks James for the inspiration!

I'm so glad you stayed until the very end @paralkarlab.bsky.social! It was my honor to present a curated subset of the top abstracts presented at #ASH24. For those that couldn't make it, it is available for viewing on the @ash-hematology.bsky.social meeting app & webcasts are available online.

Lastly, a shout out to my co-chair Sant-Rayn Pasricha (whom I will nudge onto Bluesky!) for a lot of laughs, for keeping an at-times challenging job light and fun, & for literally sharing the spotlight with me. Wouldn't have wanted to partner with anyone else. Hope to see everyone at #ASH25!

I have learned more about the breadth and depth of the #hematology field than I ever knew before. I also learned that it's near impossible to keep up with social media posts while also having the scientific program co-chair role (my bad!). 5/n

I leave #ASH24 tired (obv!) but inspired. Thank you to the basic scientists, the drug developers, the clinical trialists, the practicing physicians that bring their best science, successes & failures, & unique perspectives to this meeting. 4/n

Behind the scenes, @ash-hematology.bsky.social staff are the most professional, hard-working partners that not only care deeply about hematology but also essential topics of DEI & health advocacy. They make the magic happen. Shout out to Alice Kuaban, Kelly Rose & Patricia Frustace. 3/n

The annual @ash-hematology.bsky.social meeting is a result of dedicated work of many, many brilliant volunteers over 18+ months. Scientific Committees (shout out to the chairs!), abstract reviewers, Committee for Scientific Affairs, Program Committee, Executive Committee. It's amazing. 2/n

That's a wrap #ASH24! Co-chairing the scientific program was an unforgettable experience. Congratulations to the poster presenters, the oral abstract presenters, the invited speakers, the plenary presenters, late-breaking abstracts & those considered for 'Best of ASH'! A thread:

Apparently we are using #ASH2024! Can't wait for new science and more sun ☀️

me!